Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Current Leases: 2019-2024

Historic Current Leases for Syndax Pharmaceuticals (SNDX) over the last 6 years, with Dec 2024 value amounting to $471,000.

  • Syndax Pharmaceuticals' Current Leases fell 60.93% to $329,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $329,000, marking a year-over-year decrease of 60.93%. This contributed to the annual value of $471,000 for FY2024, which is 54.49% down from last year.
  • Per Syndax Pharmaceuticals' latest filing, its Current Leases stood at $471,000 for FY2024, which was down 54.49% from $1.0 million recorded in FY2023.
  • Syndax Pharmaceuticals' Current Leases' 5-year high stood at $1.0 million during FY2023, with a 5-year trough of $316,000 in FY2020.
  • Moreover, its 3-year median value for Current Leases was $471,000 (2024), whereas its average is $646,667.
  • As far as peak fluctuations go, Syndax Pharmaceuticals' Current Leases skyrocketed by 138.48% in 2023, and later crashed by 54.49% in 2024.
  • Syndax Pharmaceuticals' Current Leases (Yearly) stood at $316,000 in 2020, then increased by 14.24% to $361,000 in 2021, then climbed by 20.22% to $434,000 in 2022, then surged by 138.48% to $1.0 million in 2023, then plummeted by 54.49% to $471,000 in 2024.